36 results about "Kynurenine" patented technology

The invention discloses a generalized pustular psoriasis diagnosis marker based on metabonomics and application of the generalized pustular psoriasis diagnosis marker. The diagnostic marker is prepared from one or more of the following 35 compounds: pyruvic acid, alpha-ketoisovaleric acid, 2-hydroxybutyric acid, 3-hydroxybutyric acid, methane thiophosphoric acid, proline, uracil, tranexamic acid, 4-aminobutyric acid, threonine, scopoletin, dodecanol, N-methyl-L-leucine, L-cysteine-glycine and L-kynurenine. The feed additive is prepared from the following raw materials: 3-hydroxybenzoic acid, allantoin, delta-tocopherol, xylofuranose, glucose-1-phosphoric acid, pyrophosphate, taurine, L-asparagine, phthalic acid, 4-(dimethylamino) azobenzene, 5-tert-butyl-1h-indole-2, 3-dione, quinic acid, glucose, histidine, lysine, palmitic acid, 7-methylguanine, oleic acid and whale acid. The marker can be used for accurately distinguishing patients with generalized pustular psoriasis from healthy people.

A label-free method for detecting tryptophan and kynurenine in serum based on surface-enhanced Raman scattering (SERS) technology is disclosed, belonging to the field of molecular SERS detection using Raman spectroscopy. The purpose of this invention is to address the problems of expensive equipment, cumbersome operation, and time-consuming analysis in traditional methods for detecting Trp and Kyn molecules, which are difficult to meet the needs of real-time clinical testing, and the current lack of research in the field of direct and simultaneous detection of Trp and Kyn molecules in serum based on label-free SERS technology. Method: 1. Preparation of gold-core tellurium-shell nanoparticles; 2. Preparation of Au@TeNPs SERS substrate using a self-assembly method; 3. SERS detection of tryptophan and kynurenine molecules. This invention, based on the Au@TeNPs SERS substrate, achieves for the first time simultaneous and rapid SERS detection of Trp and Kyn molecules within physiological concentration ranges in serum media. The detection method is rapid, economical, and has significant potential for clinical application.

The invention discloses a generalized pustular psoriasis diagnosis marker based on metabonomics and application of the generalized pustular psoriasis diagnosis marker. The diagnostic marker is prepared from one or more of the following 35 compounds: pyruvic acid, alpha-ketoisovaleric acid, 2-hydroxybutyric acid, 3-hydroxybutyric acid, methane thiophosphoric acid, proline, uracil, tranexamic acid, 4-aminobutyric acid, threonine, scopoletin, dodecanol, N-methyl-L-leucine, L-cysteine-glycine and L-kynurenine. The feed additive is prepared from the following raw materials: 3-hydroxybenzoic acid, allantoin, delta-tocopherol, xylofuranose, glucose-1-phosphoric acid, pyrophosphate, taurine, L-asparagine, phthalic acid, 4-(dimethylamino) azobenzene, 5-tert-butyl-1h-indole-2, 3-dione, quinic acid, glucose, histidine, lysine, palmitic acid, 7-methylguanine, oleic acid and whale acid. The marker can be used for accurately distinguishing patients with generalized pustular psoriasis from healthy people.

The application relates to a reagent combination for detecting depression, a manufacturing method, a detection system and application thereof, and belongs to the technical field of instrument detection. The reagent combination for detecting depression comprises a calibrator, a quality control sample and an extraction solution of a to-be-detected compound serving as a biomarker; wherein the to-be-detected compound is at least three kinds selected from 5-hydroxyanthranilic acid, methionine, gamma-aminobutyric acid, 3,4-dihydroxyphenylacetic acid, 2-picolinic acid, quinolinic acid, kynurenine, 5-hydroxytryptamine, 3-hydroxykynurenine, 3-hydroxyanthranilic acid, dopamine and norepinephrine. The reagent combination for detecting depression and the detection system can significantly improve the accuracy of diagnosis, are convenient to detect, have good repeatability of detection data, are high in specificity, and are accurate in clinical diagnosis results.

The invention provides a molecularly imprinted material PtCo-MIP for kynurenine detection, a preparation method, application and a product, and belongs to the technical field of analytical chemistry. According to the invention, PtCo alloy is combined with a molecular imprinting technology; wherein the PtCo alloy has more excellent oxidase-like activity compared with Pt nanoparticles, and the molecular imprinting technology solves the problem of insufficient specific detection of a target factor by nano-enzyme by forming a cavity complementary with a kynurenine structure on the surface of the PtCo alloy, so that efficient and safe kynurenine specific recognition is realized, and the detection sensitivity is improved. And the blank of low-cost and high-specificity detection technology in objective diagnosis of depression is filled. The kynurenine detection kit has an extremely wide detection range on kynurenine, and the detection range and the sensitivity are far better than those of an existing commercial kit; meanwhile, the anti-interference capability is excellent, accurate detection can be performed even in a complex matrix, the detection performance is excellent, and an accurate biological basis is provided for early diagnosis of depression.

The invention discloses a generalized pustular psoriasis diagnosis marker based on metabonomics and application of the generalized pustular psoriasis diagnosis marker. The diagnostic marker is prepared from one or more of the following 35 compounds: pyruvic acid, alpha-ketoisovaleric acid, 2-hydroxybutyric acid, 3-hydroxybutyric acid, methane thiophosphoric acid, proline, uracil, tranexamic acid, 4-aminobutyric acid, threonine, scopoletin, dodecanol, N-methyl-L-leucine, L-cysteine-glycine and L-kynurenine. The feed additive is prepared from the following raw materials: 3-hydroxybenzoic acid, allantoin, delta-tocopherol, xylofuranose, glucose-1-phosphoric acid, pyrophosphate, taurine, L-asparagine, phthalic acid, 4-(dimethylamino) azobenzene, 5-tert-butyl-1h-indole-2, 3-dione, quinic acid, glucose, histidine, lysine, palmitic acid, 7-methylguanine, oleic acid and whale acid. The marker can be used for accurately distinguishing patients with generalized pustular psoriasis from healthy people.

An object of the present invention is to provide a novel composition for suppressing trimethylamine production and / or kynurenine production.SOLUTION: The means for solving the above problems is a composition for inhibiting trimethylamine production and / or kynurenine production, comprising a combination of indigestible dextrin and inulin.SELECTED DRAWING: Figure 1

The invention discloses a lung cancer soft meningeal metastasis marker and application thereof. The marker for the soft meningeal metastasis of the lung cancer comprises one or more of Hydroxyphenylic acid, Betaine, 3-Methoxytyrosine, L-Kyninuine, 1-Methoxyguanosine and 2-Hydroxyphenylethanosine, and whether a subject suffers from the soft meningeal metastasis of the lung cancer or is suspected to suffer from the soft meningeal metastasis of the lung cancer or not can be diagnosed by detecting the level of the marker in a sample of the subject. The invention has a good application prospect in diagnosis of lung cancer soft meningeal metastasis.

This invention discloses urinary metabolic biomarkers for hyperuricemia and their applications, relating to the field of metabolomics technology. It aims to overcome the shortcomings of traditional serum uric acid detection, such as susceptibility to interference, insufficient early warning capabilities, and a lack of sensitive, specific, and non-invasive biomarkers. The urinary metabolic biomarker is at least one of L-kynurenine, indole, and betaine, which can be used to prepare reagents or kits. The assessment system includes a sample analysis unit and a risk assessment model. This invention enables non-invasive and convenient detection of hyperuricemia, accurately captures early metabolic abnormalities, provides reliable risk stratification, and supports clinical auxiliary diagnosis and pathogenesis research.

The present application relates to the medical examination technical field, specifically to a kind of cancer patient psychological state monitoring method and system, comprising the following steps: detecting serum sample solution tryptophan and kynurenine concentration and operation output measured conversion rate, extract tumor entity diameter and C-reactive protein concentration, input to nonlinear regression model output physiological baseline conversion rate, execute numerical difference operation to obtain metabolic deviation residual value, when exceeding threshold, call segmented linear mapping function to generate psychological stress specific evaluation report.In the present application, by selecting tryptophan and kynurenine conversion rate as monitoring object, introducing tumor diameter and C-reactive protein to construct model to calculate physiological baseline, eliminate physiological metabolic background from measured conversion rate to obtain residual value representing pure psychological factors, realize specific quantitative evaluation of psychological stress state, eliminate masking effect of somatic pathological factors, improve evaluation accuracy and objectivity.

The invention relates to the technical field of medical examination, in particular to a cancer patient psychological state monitoring method and system.The cancer patient psychological state monitoring method comprises the following steps that a serum sample is detected, tryptophan and kynurenine concentrations are solved, the actually-measured conversion rate is calculated and output, and the tumor entity diameter and the C-reactive protein concentration are extracted; inputting the physiological baseline conversion rate into a nonlinear regression model, outputting the physiological baseline conversion rate, executing numerical difference operation to obtain a metabolic deviation residual value, and calling a piecewise linear mapping function to generate a psychological stress specificity evaluation report when the metabolic deviation residual value exceeds a threshold value. According to the method, the conversion rate of tryptophan and kynurenine is selected as a monitoring object, the tumor diameter and C-reactive protein are introduced to construct a model to solve a physiological baseline, a physiological metabolic background is removed from the actually measured conversion rate to obtain a residual value representing pure psychological factors, and specific quantitative evaluation of the psychological stress state is achieved. The body pathological factor masking effect is eliminated, and the evaluation accuracy and objectivity are improved.

The present invention relates to a biomarker for diagnosing lung cancer and methods for providing artificial intelligence-based information for diagnosing lung cancer, and more particularly to a biomarker for diagnosing lung cancer, comprising kynurenine (KN), lysophosphatidylcholine 16:0 (LPC16), lysophosphatidylcholine 18:0 (LPC18), glutamic acid (Glu), hexanoyl-L-carnitine (HC), octanoyl-L-carnitine (OC), decanoyl-L-carnitine (DC), dodecanoyl-L-carnitine (DDC), myristoyl-L-carnitine (MC) and palmitoyl-L-carnitine (PC), a biomarker composition for diagnosing lung cancer, and a method for providing artificial intelligence-based information for diagnosing lung cancer using the biomarker.As a result of establishing an artificial intelligence-based algorithm model for lung cancer diagnosis using the biomarkers for lung cancer diagnosis selected in the present invention, it was confirmed that the ability to early screen lung cancer is 90.21% sensitivity and 93.03% specificity, which is very high accuracy compared to the existing lung cancer screening method, so the present invention can effectively provide information on lung cancer diagnosis.

Methods and compositions for treating leukemia involving administering a therapeutically effective amount of an inhibitor of indoleamine 2,3 dioxygenase (IDO1). The leukemia may be is acute myeloid leukemia or acute lymphoid leukemia. The inhibitor can be a small molecule such as indiximod, epacadostat, BMS-986205, navoximod, PF-0684003, KHK2455 or LY3381916 or epacadostat. The inhibitor can be used alone or in conjunctions with other chemotherapeutic agents. IDO1 can also be inhibited using a CRISP-CAS system. The inhibitor can be administered orally, intravenously, intramuscularly, topically, arterially, or subcutaneously.

The invention relates to the field of biological medicine, and discloses a composition targeting a lactobacillus johnsonii-tryptophan metabolic axis and application of the composition. The composition comprises a traditional Chinese medicine extract and lactobacillus johnsonii, the traditional Chinese medicine extract is prepared from radix bupleuri, radix paeoniae alba, fructus aurantii immaturus and honey-fried licorice root. Traditional Chinese medicine extracts of radix bupleuri, radix paeoniae alba, fructus aurantii immaturus and honey-fried licorice root are compounded with lactobacillus johnsonii according to a specific proportion, tryptophan is promoted to be converted into 5-hydroxytryptamine, kynurenine is inhibited from being generated, depression-like behaviors are effectively relieved, the traditional Chinese medicine composition can cooperate with anticancer drugs to remarkably inhibit cancer cell growth, meanwhile, the intestinal barrier function can be improved, the intestinal immunity can be improved, and the curative effect is good. The invention provides a high-safety synergistic treatment scheme with triple effects of tumor inhibition, depression resistance and intestinal tract improvement for patients with liver cancer and depression.

The invention relates to a kit for evaluating the risk of PD-1 immune drug-related adverse reactions (irAE). The kit comprises a component for detecting a specific biomarker group, and the biomarker group comprises a protein marker selected from the group consisting of ATP6V1G1, GOT2, CD63 and CHCHD4, and / or a metabolite marker selected from the group consisting of kynurenine, tryptophan and phosphatidylcholine PC (17: 117: 1) and PC (17: 226: 7). According to the kit, by analyzing biomarker signals detected by the components of the kit, objective indexes can be provided for evaluating the risk of irAE of a patient. The kit disclosed by the invention is suitable for detecting a biological sample in an in-vitro environment and provides information support for clinical decision-making.

The present invention relates to methods for using oligosaccharide preparations to modulate animal behavior, improve animal welfare, and increase the production of gamma-aminobutyric acid, kynurenine and / or serotonin to improve animal performance.

The present invention relates to: a biomarker composition for diagnosing multiple cancers, the biomarker composition comprising metabolites; and an artificial intelligence-based method for providing information for diagnosing multiple cancers and, more specifically, to a biomarker composition for diagnosing multiple cancers and an artificial intelligence-based method for providing information for diagnosing multiple cancers, the biomarker composition comprising at least five biomarkers selected from the group consisting of valine (Val), glutamate (Glu), N-methyl-2-pyridone-5-carboxamide (2PY), tryptophan (Trp), kynurenine (KN), acetylcarnitine (AC), hexanoylcarnitine (HC), octanoylcarnitine (OC), decanoylcarnitine (DC), lauroylcarnitine (LAC), myristoylcarnitine (MC), palmitoylcarnitine (PC), 16:0 Lyso PC (LPC16), 18:0 Lyso PC (LPC18), 15:0-18:1 PC (15PC), 16:0 SM (16SM), 18:1 SM (18SM), and 24:1 SM (24SM).

Disclosed in the present invention is a 1-thienyl-β-carboline-based IDO1 and TDO dual inhibitor, selected from a 1-thienyl-β-carboline derivative having a structure as represented by formula I or a pharmaceutically acceptable salt thereof. R1 is hydrogen, fluorine, chlorine or bromine, R2 is hydrogen, methyl or trifluoromethyl, R3 is methyl, and R4 is C1-C4 linear or branched alkyl. Disclosed in the present invention is a use of the 1-thienyl-β-carboline derivative or the pharmaceutically acceptable salt thereof in the preparation of a IDO1 and TDO dual inhibitor. Disclosed in the present invention is a use of the 1-thienyl-β-carboline derivative or the pharmaceutically acceptable salt thereof in the preparation of a medicament for treating IDO1- and TDO-mediated diseases. The IDO1- and TDO-mediated diseases are central nervous system diseases associated with IDO1- and TDO-mediated tryptophan-kynurenine metabolic pathway abnormalities, specifically including depression, anxiety, Parkinson's disease and Alzheimer's disease.

The invention discloses a digital SERS kynurenine ultramicro detection method based on deep learning. The method belongs to the technical field of biomedical detection and spectral analysis, and comprises the following steps: constructing an array type SERS substrate with uniformly distributed hot spots, and collecting multi-spatial-position SERS mapping spectrums of kynurenine samples with different concentrations; then performing unified cutting, abnormal value elimination, baseline correction, denoising and normalization processing on the spectral data, completing labeling by combining sample concentration, and constructing a standardized data set; and establishing a deep learning model fusing the improved ResNet network and a self-attention module, and jointly inputting the full-spectrum features and digital features obtained by feature peak dynamic threshold binaryzation to carry out concentration regression prediction. The method has high detection sensitivity, can realize quantitative detection of kynurenine as low as 10 <-11 > mol / L, has strong robustness to noise interference, and is suitable for detection and quantitative analysis of complex biological matrixes such as serum and urine.

The invention discloses a method for label-free detection of tryptophan and kynurenine in serum based on a surface enhanced Raman scattering technology, and belongs to the field of Raman spectrum molecule SERS detection. The invention aims to solve the problems that the traditional Trp molecule and Kyn molecule detection method is expensive in equipment, tedious in operation, time-consuming in analysis and difficult to meet clinical instant detection requirements, and a blank still exists in the research field of directly and synchronously detecting Trp and Kyn molecules in serum based on an unmarked SERS (Surface Enhanced Raman Scattering) technology at present. The method comprises the following steps: 1, preparing gold-core tellurium-shell nanoparticles; 2, preparing an Au (at) TeNPs SERS substrate by a self-assembly method; and 3, detecting tryptophan and kynurenine molecules by SERS (Surface Enhanced Raman Scattering Based on the Au-coated TeNPs SERS substrate, synchronous and rapid SERS detection on Trp and Kyn molecules in a physiological concentration range in a serum medium is achieved for the first time, and the detection method is rapid and economical and has remarkable clinical application potential.

This invention provides combinations of kynurenine and antigen presenting cells (APC) for modulating immune tolerance, wherein the combinations may be used to modulate an autoimmune response, which may be of use in the treatment of Type 1 Diabetes (TID)) or alopecia areata (AA). Uses of kynurenine and antigen presenting cells (APC) as an immune modulator for the treatment of TID or AA are also provided.

The present application belongs to the technical field of molecular biology, and particularly relates to an IDO1 aptamer, nanoparticles, and a preparation method and application thereof. The present application utilizes protein-based SELEX technology to screen eight nucleic acid aptamers with small molecular weight, good IDO1 binding capacity, and high efficiency in inhibiting IDO1, and the specific nucleotide sequence is shown in any one of SEQ ID NO. 1-8. The eight nucleic acid aptamers are verified to be capable of efficiently binding to IDO1, and the eight nucleic acid aptamers and IDO1 protein are mixed and incubated to find that the concentration of kynurenine is significantly reduced, and the activity of IDO1 protein is inhibited, which provides a new idea and new tool for tumor diagnosis and treatment, and has important clinical value.

The application discloses a digital SERS kynurenine ultra-micro detection method based on deep learning and belongs to the technical field of biomedical detection and spectral analysis. An array type SERS substrate with uniform hot spot distribution is constructed, and the SERS mapping spectra of kynurenine samples with different concentrations are collected at multiple spatial positions. Then, the spectral data are uniformly cropped, outliers are removed, baseline correction, denoising and normalization are performed, and the samples are labeled in combination with the sample concentration to construct a standardized data set. A deep learning model fusing an improved ResNet network and a self-attention module is established, the full-spectrum features and the digital features obtained by dynamic threshold binarization of the characteristic peaks are jointly input, and concentration regression prediction is performed. The method has high detection sensitivity, can realize quantitative detection of kynurenine as low as 10 ‑ 11 mol / L, has strong robustness to noise interference, and is suitable for detection and quantitative analysis of complex biological matrices such as serum and urine.

The application belongs to the field of medicine, and specifically discloses application of a small molecule compound KA-C1 in preparation of a medicine for preventing or treating cardiac hypertrophy, cardiac fibrosis and / or heart failure. The application finds that kynurenine-3-monooxygenase (KMO) is an effective medicine target for treating pathological cardiac hypertrophy and cardiac fibrosis through research. Through computer-aided virtual screening, the application finds a KMO-specific agonist KA-C1, and KA-C1, as a medicine active ingredient, can directly stimulate KMO protein activity, thereby effectively resisting pathological cardiac hypertrophy and cardiac fibrosis, and further preventing or treating heart failure. Therefore, the discovery of the small molecule compound KA-C1 provides a new medicine target strategy for treating pathological cardiac hypertrophy, cardiac fibrosis and heart failure, and has important and wide application prospects.

The invention discloses a generalized pustular psoriasis diagnosis marker based on metabonomics and application of the generalized pustular psoriasis diagnosis marker. The diagnostic marker is prepared from one or more of the following 35 compounds: pyruvic acid, alpha-ketoisovaleric acid, 2-hydroxybutyric acid, 3-hydroxybutyric acid, methane thiophosphoric acid, proline, uracil, tranexamic acid, 4-aminobutyric acid, threonine, scopoletin, dodecanol, N-methyl-L-leucine, L-cysteine-glycine and L-kynurenine. The feed additive is prepared from the following raw materials: 3-hydroxybenzoic acid, allantoin, delta-tocopherol, xylofuranose, glucose-1-phosphoric acid, pyrophosphate, taurine, L-asparagine, phthalic acid, 4-(dimethylamino) azobenzene, 5-tert-butyl-1h-indole-2, 3-dione, quinic acid, glucose, histidine, lysine, palmitic acid, 7-methylguanine, oleic acid and whale acid. The marker can be used for accurately distinguishing patients with generalized pustular psoriasis from healthy people.

The application discloses application of L- kynurenine in preparation of a medicine for preventing and / or treating ultraviolet light induced skin photo-damage. The application proves that L- kynurenine has a significant anti-photo-damage effect by a UVA irradiation HaCaT cell model, can enhance mitochondrial function and promote mitochondrial biogenesis, thereby improving the antioxidant capacity of cells and reducing inflammatory reactions. The application also verifies that a hydrogel containing L- kynurenine can effectively repair mouse back skin damage caused by ultraviolet light through a UVA combined with UVB irradiation back depilation mouse model, improve the water content and antioxidant capacity of the skin, and reduce inflammatory reactions, edema, roughness, erythema or eschar and other phenomena. Therefore, the application provides a reference direction for development, utilization and popularization of L- kynurenine for preparing a medicine or a medical cosmetic product for repairing skin photo-damage.

A kind of algorithm model for depression detection, detection system, program and storage medium.The training method of the artificial intelligence model includes: constructing artificial intelligence model, its input includes the concentration of 3-4 kinds of to-be-detected compounds selected from 5-hydroxyanthranilic acid, methionine, gamma-aminobutyric acid, 3,4-dihydroxyphenylacetic acid, 2-picolinic acid, quinolinic acid, kynurenine, 5-hydroxytryptamine, 3-hydroxykynurenine, 3-hydroxyanthranilic acid, dopamine, norepinephrine, homocysteine, and the output is the risk index of suffering from severe depression;Large sample data is used to train the artificial intelligence model.The AUC of the detection model of the application is greater than or equal to 0.95, even 0.99;Accuracy rate reaches more than 90%;High sensitivity;Algorithm is simple, iterative convergence is fast, is convenient for transplantation, can be embedded into detection system, also can be used as a single data processing unit, works using encryption key or external U disk mode.